Four studies reported serious hypothyroidism, from which we found that the PD-1 or PD-L1 inhibitors had higher risk than chemotherapy (OR = 5.92, 95% CI: 1.22–28.86), especially in the subgroup with PD-1 combined with chemotherapy (see Figure S1). The gene discussed is PDCD1; the disease is hypothyroidism.